Reuters logo
4 个月前
BRIEF-Acasti Pharma provides update on Capre phase 3 development program
2017年3月30日 / 中午12点17分 / 4 个月前

BRIEF-Acasti Pharma provides update on Capre phase 3 development program

1 分钟阅读

March 30 (Reuters) - Acasti Pharma Inc

* Acasti Pharma provides update on Capre phase 3 development program

* Plans to proceed with its phase 3 development program for Capre

* Acasti Pharma Inc - outcome of end-of-phase 2 meeting with FDA confirms phase 3 program is on track to start late 2017

* Acasti Pharma- plans to conduct 2 pivotal, randomized, placebo controlled studies to evaluate efficacy, safety of Capre in patients with hypertriglyceridemia Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below